

RECEIVED
CENTRAL FAX CENTER

OCT 04 2005

FAX TRANSMISSION

DATE: October 4, 2005

PTO IDENTIFIER: Application Number 10/645,312-Conf. #7622

Inventor: Tacyoung Yoon et al.

MESSAGE TO: US Patent and Trademark Office

FAX NUMBER: (571) 273-8300

FROM: EDWARDS & ANGELL, LLP

John B. Alexander, Ph.D.

PHONE: (617) 439-4444

Attorney Dkt. #: 58288(72021)

PAGES (Including Cover Sheet): 30

CONTENTS:

Amendment Transmittal (1 page);
Amendment (28 pgs).

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 439-4444 and send the original transmission to us by return mail at the address below.


This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

EDWARDS & ANGELL, LLP
P.O. Box 55874, Boston, Massachusetts 02205
Telephone: (617) 439-4444 Facsimile: (617) 439-4170

OCT 04 2005

AMENDMENT TRANSMITTAL LETTER				Docket No. 58288(72021)	
Application No. 10/645,312-Conf. #7622		Filing Date August 20, 2003		Examiner Z. C. Tucker	
				Art Unit 1624	
Applicant(s): Taeyoung Yoon et al.					
Invention: 5-SUBSTITUTED-2-ARYLPYRAZINES					
TO THE COMMISSIONER FOR PATENTS					
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims		- 20 =		x	
Independent Claims		- 3 =		x	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					0.00
<input checked="" type="checkbox"/> Large Entity <input type="checkbox"/> Small Entity					
<input checked="" type="checkbox"/> No additional fee is required for this amendment.					
<input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of \$ _____. A duplicate copy of this sheet is enclosed.					
<input type="checkbox"/> A check in the amount of \$ _____ to cover the filing fee is enclosed.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <u>04-1105</u> as described below. A duplicate copy of this sheet is enclosed.					
<input checked="" type="checkbox"/> Credit any overpayment.					
<input checked="" type="checkbox"/> Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.					
John B. Alexander, Ph.D. Attorney Reg. No.: 48,399 EDWARDS & ANGELL, LLP P.O. Box 55874 Boston, Massachusetts 02205 (617) 439-4444				Dated: <u>October 4, 2005</u>	
I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (571) 273-0300, on the date shown below.					
Dated: October 4, 2005		Signature: <u>Bonnie S. Crespi</u> (Bonnie S. Crespi)			

OCT 04 2005

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. 571-273-8300, on the date shown below.
Dated: October 4, 2005 Signature: 
(Bonnie S. Croser)

Docket No.: 58288(72021)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Taeyoung Yoon et al.

Application No.: 10/645,312

Confirmation No.: 7622

Filed: August 20, 2003

Art Unit: 1624

For: 5-SUBSTITUTED-2-ARYLPYRAZINES

Examiner: Z. C. Tucker

AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

Applicants are in receipt of the Office Action dated July 6, 2005 and request reconsideration of the above-identified application in view of the following amendments and remarks. Please amend the above-identified application as follows:

Amendments to the Abstract begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 25 of this paper.